Intellia Therapeutics, Inc. (NTLA) Financials
NTLA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.3 billion | 250.8 million |
2023-09-30 | 1.2 billion | 205.9 million |
2023-06-30 | 1.3 billion | 218.4 million |
2023-03-31 | 1.4 billion | 227.0 million |
NTLA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -94.6 million | 35.0 million |
2023-09-30 | -105.7 million | 35.4 million |
2023-06-30 | -94.6 million | 36.4 million |
2023-03-31 | -113.2 million | 27.3 million |
NTLA Net Income
No data available :(
NTLA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 912.2 million | - | 115.3 million |
2023-09-30 | 992.5 million | - | 118.3 million |
2023-06-30 | 1.1 billion | - | 122.3 million |
2023-03-31 | 1.2 billion | - | 126.1 million |
NTLA Shares Outstanding
NTLA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 1.5 million | 109.0 million | 29.0 million | - |
2023-09-30 | 4.3 million | 113.7 million | 29.4 million | - |
2023-06-30 | 4.3 million | 115.3 million | 30.7 million | - |
2023-03-31 | 3.8 million | 97.1 million | 27.4 million | - |
NTLA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | -1.9 million | 2.5 million |
2023-09-30 | 12.0 million | 2.3 million |
2023-06-30 | 13.6 million | 2.2 million |
2023-03-31 | 12.6 million | 2.0 million |
NTLA
Price: $22.28
52 week price:
Earnings Per Share: -5.42 USD
P/E Ratio: -5.29
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Ebitda: -15.1 millionMarket Capitalization: 2.4 billion